

Fig. 1A

2/9




Fig. 1B




Fig. 1C




Fig. 2A



Fig. 2B




Fig. 2C

PD	HD	A/B	C	D	E/F
PAX8 DNA BINDING DOMAINS		PPAR $\gamma$ NUCLEAR RECEPTOR DOMAINS			

PAX8e7-PPAR $\gamma$ el: AGA CCT ACC CCG TGG TGG CAG -- AAA TGA CCA TGG TTG ACA CAG  
 PAX8e8-PPAR $\gamma$ el: CGG GCC AGG CCC TCC TCT CAG -- AAA TGA CCA TGG TTG ACA CAG  
 PAX8e9-PPAR $\gamma$ el: CCA TCG CAG GCA TGG TGG CAG -- AAA TGA CCA TGG TTG ACA CAG

Fig. 3A

6/9




Fig. 3B




Fig. 3C




Fig. 4A



anti-PPAR $\gamma$ anti-PPAR $\gamma$   
+ PPAR $\gamma$  peptide

Fig. 4B


THYROID NEOPLASM	RT-PCR	IMH
Follicular Carcinoma	5/8	7/8
Follicular Adenoma	0/20	0/20
Papillary Carcinoma	0/10	0/10
Multi-nodular Hyperplasia	0/10	0/10

Fig. 4C

THYROID FOLLICULAR CARCINOMA: t(2;3)(q13;p25)--->PAX8-PPAR $\gamma$



ACUTE PROMYELOCYTIC LEUKEMIA: t(15;17)(q22;q11-21)--->PML-RAR $\alpha$



ALVEOLAR RHABDOMYOSARCOMA: t(2;13)(q35;q14)--->PAX3-FKHR




Fig. 5






Fig. 6A




Fig. 6B